{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:45:31Z","timestamp":1779245131423,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/cgt.2015.29","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T10:37:27Z","timestamp":1435315047000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma"],"prefix":"10.1038","volume":"22","author":[{"given":"X Y","family":"Xuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q R","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P P","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"BFcgt201529_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.athoracsur.2008.12.095","volume":"87","author":"S Tomaszek","year":"2009","unstructured":"Tomaszek S, Wigle DA, Keshavjee S, Fischer S . Thymomas: review of current clinical practice. Ann Thorac Surg 2009; 87: 1973\u20131980.","journal-title":"Ann Thorac Surg"},{"key":"BFcgt201529_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/00000658-199910000-00012","volume":"230","author":"KB Wilkins","year":"1999","unstructured":"Wilkins KB, Sheikh E, Green R, Patel M, George S, Takano M et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999; 230: 562\u2013572.","journal-title":"Ann Surg"},{"key":"BFcgt201529_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molimm.2008.09.035","volume":"46","author":"A Samarakoon","year":"2009","unstructured":"Samarakoon A, Chu H, Malarkannan S . Murine NKG2D ligands: 'Double, double toil and trouble'. Mol Immunol 2009; 46: 1011\u20131019.","journal-title":"Mol Immunol"},{"key":"BFcgt201529_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/imt.11.102","volume":"3","author":"A Malhotra","year":"2011","unstructured":"Malhotra A, Shanker A . NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011; 3: 1143\u20131166.","journal-title":"Immunotherapy"},{"key":"BFcgt201529_CR5","first-page":"8","volume":"13","author":"P Spear","year":"2013","unstructured":"Spear P, Wu MR, Sentman ML, Sentman CL . NKG2D ligands as therapeutic targets. Cancer Immun 2013; 13: 8.","journal-title":"Cancer Immun"},{"key":"BFcgt201529_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727\u2013729.","journal-title":"Science"},{"key":"BFcgt201529_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","volume":"235","author":"M Champsaur","year":"2010","unstructured":"Champsaur M, Lanier LL . Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267\u2013285.","journal-title":"Immunol Rev"},{"key":"BFcgt201529_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fimmu.2012.00299","volume":"3","author":"L Fern\u00e1ndez-Messina","year":"2012","unstructured":"Fern\u00e1ndez-Messina L, Reyburn HT, Val\u00e9s-G\u00f3mez M . Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 2012; 3: 299.","journal-title":"Front Immunol"},{"key":"BFcgt201529_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2217\/imt.14.59","volume":"6","author":"T Ramutton","year":"2014","unstructured":"Ramutton T, Buccheri S, Dieli F, Todaro M, Stassi G, Meraviglia S . \u03b3\u03b4 T cells as a potential tool in colon cancer immunotherapy. Immunotherapy 2014; 6: 989\u2013999.","journal-title":"Immunotherapy"},{"key":"BFcgt201529_CR10","doi-asserted-by":"publisher","first-page":"12823","DOI":"10.1073\/pnas.1413933111","volume":"111","author":"CA Crane","year":"2014","unstructured":"Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci USA 2014; 111: 12823\u201312828.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201529_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1679\/aohc.60.9","volume":"60","author":"HK M\u00fcller-Hermelink","year":"1997","unstructured":"M\u00fcller-Hermelink HK, Wilisch A, Schultz A, Marx A . Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Arch Histol Cytol 1997; 60: 9\u201328.","journal-title":"Arch Histol Cytol"},{"key":"BFcgt201529_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00428-014-1587-5","volume":"464","author":"Y Miki","year":"2014","unstructured":"Miki Y, Hamada K, Yoshino T, Miyatani K, Takahashi K . Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type ofthymoma. Virchows Arch 2014; 464: 725\u2013734.","journal-title":"Virchows Arch"},{"key":"BFcgt201529_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/his.12279","volume":"64","author":"P Str\u00f6bel","year":"2014","unstructured":"Str\u00f6bel P, Hartmann E, Rosenwald A, Kalla J, Ott G, Friedel G et al. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology 2014; 64: 557\u2013566.","journal-title":"Histopathology"},{"key":"BFcgt201529_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1074-7613(02)00333-3","volume":"17","author":"AM Jamieson","year":"2002","unstructured":"Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH . The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17: 19\u201329.","journal-title":"Immunity"},{"key":"BFcgt201529_CR15","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1158\/0008-5472.CAN-03-2194","volume":"64","author":"JR Conejo-Garcia","year":"2004","unstructured":"Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res 2004; 64: 2175\u20132182.","journal-title":"Cancer Res"},{"key":"BFcgt201529_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571\u2013580.","journal-title":"Immunity"},{"key":"BFcgt201529_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","volume":"14","author":"D Cosman","year":"2001","unstructured":"Cosman D, M\u00fcllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123\u2013133.","journal-title":"Immunity"},{"key":"BFcgt201529_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach A, Jensen ER, Jamieson AM, Raulet DH . Rae1 and H60 ligands of the NKG2Dreceptor stimulate tumour immunity. Nature 2001; 413: 165\u2013171.","journal-title":"Nature"},{"key":"BFcgt201529_CR19","doi-asserted-by":"publisher","first-page":"31576","DOI":"10.1074\/jbc.M114.591537","volume":"289","author":"M Hagemann-Jensen","year":"2014","unstructured":"Hagemann-Jensen M, Uhlenbrock F, Kehlet S, Andresen L, Gabel-Jensen C, Ellgaard L et al. The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem 2014; 289: 31576\u201331590.","journal-title":"J Biol Chem"},{"key":"BFcgt201529_CR20","doi-asserted-by":"publisher","first-page":"12823","DOI":"10.1073\/pnas.1413933111","volume":"111","author":"CA Crane","year":"2014","unstructured":"Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci USA 2014; 111: 12823\u201312828.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201529_CR21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.4049\/jimmunol.1303275","volume":"193","author":"F Uhlenbrock","year":"2014","unstructured":"Uhlenbrock F, Hagemann-Jensen M, Kehlet S, Andresen L, Pastorekova S, Skov S . The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway. J Immunol. 2014; 193: 1654\u20131665.","journal-title":"J Immunol."}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201529","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:29:34Z","timestamp":1647952174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFcgt201529"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2015.29","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]},"assertion":[{"value":"23 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}